Ongoing Assessments & Recent Research.
Easy access to our work
Our Origin Story.
ICER President Dr. Steve Pearson explains why he founded an organization to advance the use of evidence to improve health care affordability and access for all patients and their families.
Featured News & Insights.
Learn about our latest work.
The ICER Impact.
New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $500 million
Engaged with over 300 patient groups and patient reps
We recently celebrated our 15th anniversary! Learn more.
Dr. Melanie Whittington, ICER’s Director of Health Economics, received the Bernie O’Brien New Investigator Award, which recognizes those who have shown evidence of exceptional promise based on their emerging body of technical and scholarly work in the field of health economics. Learn more.
Easy access to our latest policy papers
Out of 10 identified drugs that had substantial 2020 price increases net of rebates on top of already high current spending, seven were not supported by new clinical evidence; net price increases on these seven drugs cost Americans an additional $1.67 billion in annual drug spend, of which nearly $1.4 billion was due to a single drug alone: Humira.
ICER received a new grant from The Commonwealth Fund to evaluate procedural and methodological changes that could further support health equity goals in health technology assessment (HTA). The findings from this effort will guide ICER’s update to its value assessment framework and inform the work of other HTA groups worldwide.